Skip to main content
Clinical Trials/JPRN-UMIN000028605
JPRN-UMIN000028605
Completed
未知

A retrospective study for ALK positive Lung Cancer - The Clinical Benefits of Sequential Therapy using Crizotinib followed by Alectinib in Clinical Practice: A Multicenter Retrospective Study. - (WJOG9516L) - A retrospective study for ALK positive Lung Cancer

West Japan Oncology Group0 sites700 target enrollmentAugust 9, 2017

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
West Japan Oncology Group
Enrollment
700
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 9, 2017
End Date
March 9, 2019
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • No prior exposure of ceritinib before crizotinib or alectinib, regardless of clinical trial or practice.

Outcomes

Primary Outcomes

Not specified

Similar Trials